Compare Futu Holdings Ltd (FUTU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Incyte Corporation — how do they compare? Futu Holdings Ltd trades at $106 (market cap $14.74B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Futu Holdings Ltd pays a 2.47% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FUTU | INCY | |
|---|---|---|
Market Cap | $14.74B | $24.54B |
Sector | Financials | Health |
52-Week High | $199.04 | $129.93 |
52-Week Low | $89.76 | $81.61 |
Enterprise Value | $14.59B | $20.04B |
Dividend Yield | 2.47% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
